Table 3.
Functions of dysregulated miRNAs in chronic myeloid leukemia.
| miR Name | Dysregulation in cancer | References |
|---|---|---|
| hsa-miR-1260a | Down-regulated in follicular B-cell lymphoma | (20) |
| hsa-miR-27a-3p | Involved in tumor growth: cell proliferation and cell invasion | (21) |
| hsa-miR-140-3p | Chemoresistance in osteosarcoma and colon cancer | (22) |
| mmu-miR-374b-5p | Inhibits cell migration, proliferation and invasion in cervical cancer | (23) |
| hsa-miR-143-3p | Low expression level contributes to tumor development, differentiation, proliferation, invasion and metastasis | (24) |
| hsa-miR-181c-5p | Inhibits chemoresistance in chronic myelocytic leukemia | (25) |
| hsa-miR-26b-5p | Down-regulated in breast cancer | (26) |
| hsa-miR-212-3p | Inhibits cell proliferation and promotes apoptosis | (27) |
| hsa-miR-29c-3p | Deregulated in hematological malignances | (28) |
| hsa-miR-26a-1-3p | Tumor suppressor | (29) |
| hsa-miR-181a-5p | Downregulation in resistance to imatinib | (30, 31) |
| hsa-miR-19a-3p | Potential biomarker for CML | (32) |
| hsa-miR-363-3p | Tumor suppressor in gastric cancer | (33) |
| hsa-miR-30d-5p | Downregulation in resistance to imatinib | (30, 31) |
| hsa-miR-10a-5p | Biomarker of drug response in CML | (34) |
| hsa-miR-29a-3p | Deregulated in hematological malignances | (28) |
| hsa-miR-16-5p | Regulation of cell cycle and apoptosis in myeloid leukemogenesis | (35) |
| hsa-miR-486-5p | Expression increased in erythroid differentiation in CML | (36) |
| hsa-miR-345-5p | Tumor suppressor in pancreatic cancer | (37) |
| hsa-miR-26a-5p | Tumor suppressor | (29) |
| hsa-miR-18a-3p | Potential biomarker for CML | (32) |
| hsa-miR-27b-3p | Oncogene; expression increased in lymphoma | (38) |
| hsa-miR-374a-5p | Promotes proliferation and migration of transformed mesenchymal stem cells | (39) |
| hsa-miR-362-5p | Induces apoptosis resistance and cell proliferation in gastric cancer | (40) |
| hsa-let-7g-5p | Downregulated in Burkitt's lymphoma | (41) |
| hsa-miR-324-3p | Overexpression promotes cell growth and decreases apoptosis | (42) |
| hsa-miR-550a-5p | Tumor suppressor | (43) |
| hsa-miR-125a-3p | Induces apoptosis in pancreatic cancer | (44) |
| hsa-miR-106b-5p | Inhibits metastasis and invasion colorectal cancer cells | (45) |
| hsa-miR-191-5p | Disregulated in human gliobastoma tissues | (46) |
| hsa-miR-15b-3p | High expression in poor prognosis for hepatocellular carcinoma | (47) |
| hsa-miR-328-3p | CML progression | (48) |
| hsa-miR-222-3p | Cancer development as oncomiR or as oncosuppressor | (49) |
| hsa-miR-139-5p | Antimetastic and anti-oncogenic activity | (50) |
| hsa-miR-92a-3p | Higher levels in acute myeloid leukemia and acute lymphoblastic leukemia | (51) |
| hsa-miR-628-3p | Inhibits proliferation of acute myeloid leukemia cells | (52, 53) |
| hsa-miR-150-5p | CML progression; CML biomarker | (54) |
| hsa-miR-574-3p | Tumor suppressor in ovarian cancer | (55) |
| hsa-miR-484 | Highly expressed in breast cancer patients | (56) |
| hsa-miR-127-3p | Tumor suppressors in gastric cancer | (57) |
| hsa-miR-146a-5p | Development and maintenance of neoplastic processes | (58) |
| hsa-miR-193a-5p | Low expression in lung cancer | (59) |
| hsa-miR-342-3p | Suppresses acute myeloid leukemia cell proliferation | (60) |
| hsa-miR-7-1-3p | Up-regulated in metastatic prostate cancer | (61) |
| mmu-miR-134-5p | Cancer cell proliferation | (62) |
| hsa-miR-409-3p | Tumor suppressor in endometrial carcinoma cells | (63) |
Fc, fold change; miR, microRNA.